Qualigen Therapeutics (NASDAQ:QLGN) Posts Quarterly Earnings Results

Qualigen Therapeutics (NASDAQ:QLGN) announced its quarterly earnings results on Friday. The company reported ($4.68) earnings per share (EPS) for the quarter, Zacks reports.

Qualigen Therapeutics Stock Performance

Shares of QLGN stock traded up $0.20 during trading hours on Friday, reaching $2.73. The company had a trading volume of 674,531 shares, compared to its average volume of 1,034,586. Qualigen Therapeutics has a one year low of $1.61 and a one year high of $8.81. The business has a fifty day moving average price of $3.49 and a 200-day moving average price of $3.21. The firm has a market cap of $4.63 million, a PE ratio of -0.36 and a beta of 0.24.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on QLGN shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Qualigen Therapeutics in a report on Wednesday, October 8th. Wall Street Zen upgraded Qualigen Therapeutics to a “sell” rating in a research report on Saturday, October 11th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

About Qualigen Therapeutics

Qualigen Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints.